Pharmaceutical Investing Moleculin Expects to Meet FDA IND Filing Requirements for its Pancreatic Cancer Drug Candidate with Development Work in Australia
Pharmaceutical Investing Moleculin’s Breakthrough Discovery of a New Molecule for Cancer Treatment Advances to Development Agreement with the University of Iowa
Pharmaceutical Investing Moleculin Announces Patients Treated in FDA Approved Phase I/II Annamycin Clinical Trial
Pharmaceutical Investing Moleculin Enters Agreement with Seidman Cancer Center to Conduct Leukemia Clinical Trials
Pharmaceutical Investing Moleculin Announces Grant-Funded Collaboration to Expand Understanding of New Discovery
Moleculin Announces Collaboration with Emory University to Develop Novel Treatment of Pediatric Brain Cancer
